LLY Stock Alert: What to Know as Eli Lilly Teams Up With CVS on Weight-Loss Drugs

LLY Stock Alert: What to Know as Eli Lilly Teams Up With CVS on Weight-Loss Drugs Wajeeh Khan Wed, August 5, 2026 at 9:50 PM GMT+2 2 min read LLY CVS Eli Lilly (LLY) stock extended gains on Wednesday after the pharmaceutical behemoth announced a new direct-to-consumer (DTC) collaboration with CVS Health (CVS). The press release said this team-up aims to improve patient access, affordability, and pharmacy support for Eli Lilly's blockbuster weight-loss treatments, Zepbound and Foundayo. More News from Barchart Jeff Bezos Says He's Selling $1 Billion In Amazon Stock Every Year to Fund Blue Origin — 'It's The Most Important Work I'm Doing' Apple's New CEO Is Bringing a Familiar Face Back From Retirement.

The Shift Is Happening. Here's a Realistic Roadmap Toward Generating $1,000 a Month in Options Trading Income Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else.

At the time of writing, Eli Lilly shares are up more than 35% versus their April low. www. barchart.

com Why the CVS Deal Is Bullish for Eli Lilly Stock Under the expanded partnership, CVS has agreed to integrate Lilly's weight-loss therapies into its connected care network. Eligible patients will now be able to connect 24/7 with MinuteClinic clinicians, view transparent cash-pay and reimbursed pricing via the CVS Health app, and collect prescriptions across 9,000 local CVS retail pharmacies without recurring membership fees. For LLY stock, the CVS collaboration represents a high-impact commercial victory.

By removing distribution friction and lowering telehealth visit costs to just $29, it's set to broaden retail access, boost prescription fill rates, and solidify the giant's already dominant footprint in the rapidly expanding obesity treatment market. Note that Eli Lilly currently pays a dividend yield of 0. 6% as well.

What Else Is Driving LLY Shares Higher Today? Eli Lilly shares are also rallying on Aug. 5 because the company posted better-than-expected Q2 earnings and issued impressive guidance for the full year.

Overall revenue soared 48% year-on-year, spearheaded by massive demand for its diabetes therapy Mounjaro ($9. 94 billion) and weight-loss drug Zepbound ($4. 93 billion).

Lilly's adjusted earnings per share (EPS) also came in at a robust $8. 38, despite absorbing $3. 03 a share in acquired research and development charges.

Crucially, management expects that strength to persist, raising its full-year guidance to a range of $85 billion to $87 billion. In short, a powerful combination of raised guidance and improved pharmacy distribution reaffirms LLY's strong growth trajectory for 2026 and beyond. Story Continues How Wall Street Recommends Playing Eli Lilly Lilly has already joined the trillion-dollar club this year, but Wall Street believes it could rip higher in the second half of 2026.

The consensus rating on LLY shares remains at "Strong Buy," with the mean price target of $1,292 indicating potential upside of nearly 12% from here. www. barchart.

com On the date of publication, Wajeeh Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.